PAH patients with cardiovascular disease risk had similar hospitalization and mortality rates as those without after a ...

Columnist Anna Jeter is delighted to find themes that are relevant to her life in the fictional narratives of writers and ...

Columnist Colleen Steele says that glimmers are like an antidote to some of the events that spark her caregiving anxiety.

Following the first sale of Yutrepia to treat certain types of PH, Liquidia has received $50 million under its financing ...

Adding Winrevair treatment significantly reduced the risk of clinical worsening in people with a recent PAH diagnosis, per a ...

A Phase 3 clinical trial testing the experimental daily oral treatment ralinepag in people with PAH has completed enrollment.

With patient enrollment now complete, topline results are expected early next year from a Phase 3 trial testing PAH treatment ...

Acceptance into the FDA’s Total Product Life Cycle Advisory Program (TAP) pilot will give the company more opportunities to interact with regulatory authorities. It comes after the company’s Gradient ...

LungFit PH 2 is a smaller, lightweight, transport-ready version of the first-generation LungFit PH the FDA approved in 2022. Before the new device can be marketed, the company must ask the FDA to ...

This clinical study (NCT06899815) seeks to enroll about 116 healthy individuals in China, ages 18 to 45. Around 68 participants will be randomly assigned to receive a single dose of F230 or a placebo ...